Get the Stockscreener App
0.8263
1.89%
0.0153
After Hours:
.82
-0.0063
-0.76%
Xortx Therapeutics Inc stock is traded at $0.8263, with a volume of 105.85K.
It is up +1.89% in the last 24 hours and down -7.93% over the past month.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$0.811
Open:
$0.8498
24h Volume:
105.85K
Relative Volume:
0.92
Market Cap:
$4.31M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-82.63
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
+0.16%
1M Performance:
-7.93%
6M Performance:
-10.19%
1Y Performance:
-51.39%
1-Day Range:
$0.8151
$0.86
1-Week Range:
$0.791
$0.86
52-Week Range:
$0.6608
$2.51
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.8263 | 4.38M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
What technical models suggest about XORTX Therapeutics Inc.’s comebackQuarterly Portfolio Review & Precise Trade Entry Recommendations - Newser
Is it time to cut losses on XORTX Therapeutics Inc.July 2025 PostEarnings & Detailed Earnings Play Strategies - Newser
Pattern recognition hints at XORTX Therapeutics Inc. upside2025 Key Lessons & Free Verified High Yield Trade Plans - Newser
Strategies to average down on XORTX Therapeutics Inc.Market Trend Report & Intraday High Probability Setup Alerts - Newser
XORTX Therapeutics Inc. stock trendline breakdownJuly 2025 Patterns & Free Community Consensus Stock Picks - Newser
Real time breakdown of XORTX Therapeutics Inc. stock performanceJuly 2025 Patterns & Weekly High Momentum Picks - Newser
How to track smart money flows in XORTX Therapeutics Inc.Trade Ideas & Long-Term Investment Growth Plans - Newser
Building trade automation scripts for XORTX Therapeutics Inc.Quarterly Investment Review & Advanced Technical Signal Analysis - Newser
Is XORTX Therapeutics Inc. building a consolidation baseTrade Ideas & AI Optimized Trading Strategy Guides - Newser
Published on: 2025-09-12 12:52:08 - Newser
Multi factor analysis applied to XORTX Therapeutics Inc.Quarterly Trade Review & AI Driven Stock Movement Reports - Newser
Using Ichimoku Cloud for XORTX Therapeutics Inc. technicals2025 Pullback Review & High Accuracy Trade Signal Alerts - Newser
XORTX Therapeutics Inc. stock momentum explained2025 Market Overview & Long-Term Growth Portfolio Plans - Newser
Will XORTX Therapeutics Inc. continue its uptrendBuy Signal & Expert Curated Trade Ideas - Newser
How to integrate XORTX Therapeutics Inc. into portfolio analysis tools2025 Key Lessons & Weekly Top Gainers Alerts - Newser
Has XORTX Therapeutics Inc. formed a bullish divergence2025 Year in Review & Long-Term Capital Growth Ideas - Newser
Published on: 2025-09-12 01:56:47 - Newser
Tools to monitor XORTX Therapeutics Inc. recovery probabilityJuly 2025 Trends & Precise Trade Entry Recommendations - Newser
Reversal indicators forming on XORTX Therapeutics Inc. stockJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - Newser
Should you wait for a breakout in XORTX Therapeutics Inc.July 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Drawdown in XORTX Therapeutics Inc. May Be Nearing EndJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
trend analysis for xortx therapeutics inc. this weekJuly 2025 Selloffs & Verified Entry Point Detection - Newser
Applying Elliott Wave Theory to XORTX Therapeutics Inc.July 2025 Earnings & Smart Investment Allocation Insights - Newser
Understanding XORTX Therapeutics Inc.’s price movement2025 Year in Review & Fast Moving Stock Trade Plans - Newser
Institutional scanner results for XORTX Therapeutics Inc.Market Volume Report & AI Enhanced Trading Alerts - Newser
Published on: 2025-09-10 00:06:40 - Newser
What moving averages say about XORTX Therapeutics Inc.Market Growth Summary & Daily Chart Pattern Signals - Newser
Combining machine learning predictions for XORTX Therapeutics Inc.Insider Buying & AI Enhanced Trading Signals - Newser
Can XORTX Therapeutics Inc. disrupt its industryJuly 2025 Market Mood & Daily Technical Stock Forecast Reports - Lancaster City Council
Visual analytics tools that track XORTX Therapeutics Inc. performanceWeekly Stock Report & Free High Return Stock Watch Alerts - Newser
Should you hold or exit XORTX Therapeutics Inc. nowShare Buyback & AI Powered Market Entry Strategies - Newser
Is XORTX Therapeutics Inc. vulnerable to short sellersQuarterly Market Summary & Fast Gaining Stock Reports - Lancaster City Council
IPO Launch: Can XORTX Therapeutics Inc. disrupt its industryWall Street Watch & Risk Managed Investment Entry Signals - Lancaster City Council
XORTX Therapeutics goes ‘toe to toe’ with gout by accelerating its lead drug program targeting this complex disease - BNN Bloomberg
Chart overlay techniques for tracking XORTX Therapeutics Inc.Earnings Performance Report & Risk Controlled Swing Alerts - Newser
Published on: 2025-09-09 06:05:05 - Newser
Visual trend scoring systems applied to XORTX Therapeutics Inc.Recession Risk & Fast Exit/Entry Strategy Plans - Newser
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):